Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | rabbit |
isotype | IgG |
clonality | polyclonal |
concentration | 1 mg/mL |
applications | IHC, WB |
reactivity | human |
available sizes | 10 µL, 100 µL |
rabbit anti-SOD1 polyclonal antibody 1026
$100.00 – $2,600.00
Antibody summary
- Rabbit polyclonal to Superoxide Dismutase 1 (SOD)
- Suitable for: WB,IHC
- Reacts with: Hu presumed Guinea Pig, Ms, Dog, Rat
- Isotype: IgG
- 100 µL, 10 µL
rabbit anti- sod1 polyclonal antibody 1026
antibody |
---|
Database link: human P00441 mouse P08228 rat P07632 |
Tested applications WB,IHC |
Recommended dilutions WB: 1:2000-10000, IHC: 1:500-2000, Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections. |
Immunogen Between 104 and C-terminus |
Size and concentration 100µL and 1 mg/mL |
Form liquid |
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles. |
Storage buffer Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide |
Purity affinity purified |
Clonality polyclonal |
Isotype IgG |
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720 |
Isotype control Rabbit polyclonal - Isotype Control |
target relevance |
---|
Protein names Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) (Superoxide dismutase 1) (hSod1) |
Gene names SOD1,SOD1 |
Protein family Cu-Zn superoxide dismutase family |
Mass 15936Da |
Function Destroys radicals which are normally produced within the cells and which are toxic to biological systems. |
Catalytic activity CATALYTIC ACTIVITY: Reaction=2 H(+) + 2 superoxide = H2O2 + O2; Xref=Rhea:RHEA:20696, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240, ChEBI:CHEBI:18421; EC=1.15.1.1; Evidence=; |
Subellular location Cytoplasm. Nucleus. Note=Predominantly cytoplasmic; the pathogenic variants ALS1 Arg-86 and Ala-94 gradually aggregates and accumulates in mitochondria. |
Structure Homodimer; non-disulfide-linked (By similarity). Homodimerization may take place via the ditryptophan cross-link at Trp-33. Heterodimer with SOD1 (PubMed:31292775). The heterodimer CCS:SOD1 interacts with SLC31A1; this heterotrimer is Cu(1+)-mediated and its maintenance is regulated through SOD1 activation (PubMed:31292775). Interacts with DAOA; the interaction is direct (PubMed:30037290). |
Post-translational modification Unlike wild-type protein, the pathogenic variants ALS1 Arg-38, Arg-47, Arg-86 and Ala-94 are polyubiquitinated by RNF19A leading to their proteasomal degradation. The pathogenic variants ALS1 Arg-86 and Ala-94 are ubiquitinated by MARCH5 leading to their proteasomal degradation.; The ditryptophan cross-link at Trp-33 is responsible for the non-disulfide-linked homodimerization. Such modification might only occur in extreme conditions and additional experimental evidence is required.; Palmitoylation helps nuclear targeting and decreases catalytic activity.; Succinylation, adjacent to copper catalytic site, probably inhibits activity. Desuccinylation by SIRT5 enhances activity. |
Involvement in disease DISEASE: Amyotrophic lateral sclerosis 1 (ALS1) [MIM:105400]: A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Spastic tetraplegia and axial hypotonia, progressive (STAHP) [MIM:618598]: An autosomal recessive, neurologic disorder characterized by loss of motor abilities in the first year of life, after which severe, progressive spastic tetraparesis develops. Affected individuals have severe axial hypotonia, hyperekplexia, hypertonia, and myokymia, reflecting upper motor neuron involvement. Cognitive development may be affected. Note=The disease is caused by variants affecting the gene represented in this entry. |
Target Relevance information above includes information from UniProt accession: P00441 |
The UniProt Consortium |
Publications
pmid | title | authors | citation |
---|---|---|---|
We haven't added any publications to our database yet. |
relevant to this product |
---|
Western blot IHC |
# | |||
---|---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.